Trabectedin as second line and beyond in advanced leiomyosarcoma

MLA

Julien Domont, et al. “Trabectedin as Second Line and beyond in Advanced Leiomyosarcoma.” Journal of Clinical Oncology, vol. 32, May 2014, p. e21522. EBSCOhost, https://doi.org/10.1200/jco.2014.32.15_suppl.e21522.

APA

Julien Domont, Philippe Terrier, Florence Fayard, Laurence Vilcot, Arslane Skander Rahal, Olivier Mir, Axel Le Cesne, Sylvie Bonvalot, Cécile Le Péchoux, & Chahinez Rahal. (2014). Trabectedin as second line and beyond in advanced leiomyosarcoma. Journal of Clinical Oncology, 32, e21522. https://doi.org/10.1200/jco.2014.32.15_suppl.e21522

Chicago

Julien Domont, Philippe Terrier, Florence Fayard, Laurence Vilcot, Arslane Skander Rahal, Olivier Mir, Axel Le Cesne, Sylvie Bonvalot, Cécile Le Péchoux, and Chahinez Rahal. 2014. “Trabectedin as Second Line and beyond in Advanced Leiomyosarcoma.” Journal of Clinical Oncology 32 (May): e21522. doi:10.1200/jco.2014.32.15_suppl.e21522.